Protective Effect of Val129-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease
Natalia Fernández-Borges
1, Juan Carlos Espinosa
1, Alba Marín-Moreno, Patricia Aguilar-Calvo, Emmanuel A. Asante, Tetsuyuki Kitamoto, Shirou Mohri, Olivier Andréoletti, and Juan María Torres
Author affiliations: Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (CISA-INIA); Valdeolmos, Madrid, Spain (N. Fernández-Borges, J.C. Espinosa, A. Marín-Moreno, P. Aguilar-Calvo, J.M. Torres); MRC Prion Unit, Department of Neurodegenerative Disease, University College London, Institute of Neurology, London, UK (E.A. Asante); Tohoku University Graduate School of Medicine, Sendai, Japan (T. Kitamoto, S. Mohri); UMR INRA ENVT 1225, Interactions Hôtes Agents Pathogènes, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France (O. Andréoletti)
Main Article
Figure 2
Figure 2. Protease-resistant prion protein distribution pattern in brains of prion protein humanized transgenic mice inoculated with variant Creutzfeldt-Jakob disease (vCJD) on second passage. A, B) TgMet129 mice inoculated with vCJD. C) TgMet/Val129 mice inoculated with vCJD. D, E) TgVal129 mice inoculated with vCJD propagated in TgMet129 mice. Original magnification ×20 for all panels.
Main Article
Page created: August 14, 2017
Page updated: August 14, 2017
Page reviewed: August 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.